## GEHC: GE HealthCare Technologies Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -0.4% below STRENGTH zone (4.0-10.0%); PEG 2.50 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: declining volume (38% of avg), momentum weakening (-1.7% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($79.71)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 5
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. GE HealthCare Technologies Inc. $GEHC Shares Acquired by Valicenti Advisory Services Inc.**
- Source: MarketBeat | 20251228T115724 | Bullish | Relevance: 100%
- Valicenti Advisory Services Inc. increased its stake in GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 22.6% in the third quarter, now holding 68,107 shares valued at $5.12 million. Other institutional investors like Dodge & Cox, Norges Bank, and Holocene Advisors LP have also made significant moves in GEHC shares, with 82.06% of the stock owned by institutional investors. Despite a "Moderate Buy" consensus rating and an average price target of $87.09 from Wall Street analysts, the company's financial performance shows a market cap of $38.1 billion and recent positive quarterly earnings results.

**2. GE HealthCare CEO Peter Arduini is forging a new chapter while drawing on Jack Welch’s legacy**
- Source: Fortune | 20251228T110202 | Bullish | Relevance: 92%
- GE HealthCare CEO Peter Arduini discusses leading the company post-spin-off from General Electric, drawing on GE's legacy and Jack Welch's leadership principles while adapting to modern medical technology and digital health landscapes. He highlights the company's significant increase in R&D investment and focus on lean principles, innovation, and global market strategies, particularly in China. Arduini emphasizes authenticity, communication, and empowering employees to live the company's values in his leadership approach.

**3. The Future of Bone Sonometer Market 2032 Industry Forecast**
- Source: openPR.com | 20251229T072740 | Bullish | Relevance: 82%
- The Bone Sonometer Market is projected to grow from USD 1,336.8 Mn in 2025 to USD 1,996.8 Mn by 2032, exhibiting a CAGR of 5.9%. This growth is driven by rising industry demand, expanding applications, and technological advancements, according to a report by Coherent Market Insights. The report provides a comprehensive analysis of market drivers, restraints, opportunities, and competitive landscape, with a detailed regional assessment to inform strategic business decisions.

**4. Patient Liaison Assistance Market Is Going to Boom |McKesson Corporation • 2. Cardinal Health**
- Source: openPR.com | 20251229T145245 | Somewhat-Bullish | Relevance: 70%
- Worldwide Market Reports has released a new study predicting substantial growth for the "Patient Liaison Assistance Market." The report offers a comprehensive analysis of market dynamics, competitive landscape including key players like McKesson and Cardinal Health, and segmental highlights by types and applications. It also provides regional insights, research methodology, and actionable intelligence to support business growth and investment decisions.

**5. Exchange Traded Concepts LLC Acquires New Shares in Companhia de saneamento Basico Do Estado De Sao Paulo - Sabesp $SBS**
- Source: MarketBeat | 20251227T090903 | Neutral | Relevance: 56%
- Exchange Traded Concepts LLC recently acquired 69,531 shares of Companhia de saneamento Basico Do Estado De Sao Paulo - Sabesp (NYSE:SBS) for approximately $1.73 million, establishing a new position in Q3. The utilities provider reported Q3 EPS of $0.34, significantly beating analyst estimates of $0.07, and revenues of $4.69 billion. SABESP also announced a 1.02964697 stock split effective December 29th and a special dividend of $0.4772 payable on May 11th.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-11 | Citigroup | $88 | $83 | +6% |
| 2025-12-11 | Jefferies | $105 | $95 | +11% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-11 | Citigroup | main | Neutral |
| 2025-12-11 | Jefferies | main | Buy |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 46.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 11.4% (-0.2%)
- Blackrock Inc.: 8.0% (+1.9%)
- Dodge & Cox Inc.: 6.0% (+16.8%)
- Capital Research Glo: 5.5% (+25.0%)
- State Street Corpora: 4.3% (-0.1%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-1.7% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 2.50 elevated, pricing in significant growth expectations. Forward P/E 16.9x stretched relative to 8% growth. Quality metrics strong (ROE 24%). Analyst sentiment positive (2 raises, avg +8%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $38.0B |
| Beta | 1.24 |
| 52W Range | $57.65 - $94.80 |
| Short Interest | 3.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.50 |
| Forward P/E | 16.9 |
| Current P/E | 18.3 |
| YoY Growth | 8.4% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 1.2% to -0.4% (-1.7% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 4.4pp (needs >4.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.12x) but short-term weakness (below SMA20). RSI neutral at 56. Volume at 38% of 20MA suggests lack of conviction. OFD pattern: -SUL (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -0.43% (CS: 39) | Neutral |
| RSI_14 | 56.3 | Neutral |
| MACD Histogram | -0.31 | Bearish |
| vs SMA20 | 1.000x | Below |
| vs SMA50 | 1.058x | Above |
| vs SMA200 | 1.117x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $83.15
- **Stop Loss:** $79.71 (4.1% risk)
- **Target:** $86.59 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 401
- **Position Value:** $33,343.15
- **Portfolio %:** 33.34%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.15x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with selective risk appetite and defensive rotation. VIX at 14.2 (2nd percentile) signals low volatility, while positive yield curve (+58bps) and stable economic indicators support continued expansion. Market breadth at 58.7% shows decent participation, but rotation into defensive names and Fed liquidity concerns warrant measured positioning.*

### Earnings

**Next:** 2026-02-12 (Est: $1.40)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.05 | $1.07 | +2.2% |
| 2025Q2 | $0.92 | $1.06 | +15.4% |
| 2025Q1 | $0.91 | $1.01 | +10.6% |
| 2024Q4 | $1.26 | $1.45 | +14.8% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*